Alberta Investment Management Corp Invests $3.84 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Alberta Investment Management Corp purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 58,400 shares of the biotechnology company's stock, valued at approximately $3,839,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Fifth Third Bancorp increased its holdings in BioMarin Pharmaceutical by 13.9% in the 4th quarter. Fifth Third Bancorp now owns 1,351 shares of the biotechnology company's stock valued at $89,000 after buying an additional 165 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its stake in BioMarin Pharmaceutical by 0.8% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 21,105 shares of the biotechnology company's stock worth $1,483,000 after acquiring an additional 173 shares in the last quarter. Advisors Asset Management Inc. raised its stake in BioMarin Pharmaceutical by 1.6% during the third quarter. Advisors Asset Management Inc. now owns 11,451 shares of the biotechnology company's stock worth $805,000 after acquiring an additional 180 shares in the last quarter. TD Private Client Wealth LLC lifted its holdings in shares of BioMarin Pharmaceutical by 57.4% in the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 186 shares during the last quarter. Finally, First Hawaiian Bank boosted its stake in shares of BioMarin Pharmaceutical by 1.4% in the 4th quarter. First Hawaiian Bank now owns 14,700 shares of the biotechnology company's stock valued at $966,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Trading Down 0.7 %

Shares of BMRN stock traded down $0.48 during mid-day trading on Friday, hitting $68.25. The company's stock had a trading volume of 2,348,882 shares, compared to its average volume of 1,616,799. The company has a market cap of $13.01 billion, a PE ratio of 31.02, a P/E/G ratio of 0.58 and a beta of 0.28. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27. The company's fifty day simple moving average is $64.84 and its 200-day simple moving average is $71.05. BioMarin Pharmaceutical Inc. has a 52 week low of $60.63 and a 52 week high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a return on equity of 10.10% and a net margin of 14.96%. The business had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. As a group, equities research analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BMRN has been the subject of several research reports. Citigroup increased their price objective on shares of BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a "neutral" rating in a research note on Thursday. Robert W. Baird lowered their price target on shares of BioMarin Pharmaceutical from $72.00 to $65.00 and set a "neutral" rating for the company in a report on Wednesday, October 30th. Royal Bank of Canada reissued a "sector perform" rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday. Wedbush restated an "outperform" rating and set a $94.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday. Finally, UBS Group increased their target price on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a research report on Thursday. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $93.81.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.